IMARK works in close interaction with (pre)clinical oncology research groups at the University of Antwerp. Over the last years a multitude of oncology models, both orthotopic and subcutaneous, have been developed and characterized by molecular imaging, molecular biology and immunohistochemistry. Based on this platform novel radiotracers for in vivo tumor-phenotyping are developed and validated. Currently, we have programs on assessing tumor phenotypes and monitoring therapy response with focus on proliferation (FET, FDG), hypoxia (F-MISO) and cell death (CP18). Ultimately, we aim to bring innovative radiotracers to the clinical practice for better stratification of patients and improved therapy response monitoring.